Literature DB >> 30315418

PET/CT features discriminate risk of metastasis among single-bone FDG lesions detected in newly diagnosed non-small-cell lung cancer patients.

Chae Hong Lim1, Tae Ran Ahn2, Seung Hwan Moon1, Young Seok Cho1, Joon Young Choi1, Byung-Tae Kim1, Kyung-Han Lee3.   

Abstract

OBJECTIVES: We investigated the capacity of fluorodeoxyglucose (FDG) PET/CT features for stratifying probability of metastasis for single-bone FDG lesions in non-small-cell lung cancer (NSCLC).
METHODS: Subjects were 118 newly diagnosed NSCLC patients with a solitary bone FDG lesion and no evidence of other distant metastasis based on PET/CT, brain MRI, and contrast-enhanced chest CT. Bone lesion SUVmax and CT findings, primary tumor SUVmax, clinical T stage, and N stage were analyzed.
RESULTS: The bone lesions were determined by biopsy, characteristic MRI findings and clinical follow-up to be metastatic in 33 (28.0%) and benign in 85 cases (72.0%). A cutoff bone SUVmax of 4.3 showed good diagnostic performance (81.8% sensitivity, 84.7% specificity, and 83.9% accuracy), but there was considerable overlap. Bone lesion PET/CT features of SUVmax ≤ 2, osteosclerotic rim or fracture correctly diagnosed 20/20 benign, while SUVmax > 10, soft-tissue mass or bone destruction correctly diagnosed 18/18 metastatic cases. In the remaining 80 cases, bone features of SUVmax > 4.3 and osteolytic change, and lung tumor features of SUVmax > 6.4, ≥ T2 stage (n = 70), and ≥ N1 stage (n = 43) favored metastasis. The presence of one or less of these features correctly diagnosed 38/38 benign, while the presence of four or more features correctly diagnosed 5/5 metastatic cases. The 37 cases with two or three features had either benign (n = 27) or metastatic bone disease (n = 10).
CONCLUSION: Combining bone lesion and lung tumor PET/CT features can help stratify risk of bone metastasis in these patients. KEY POINTS: • In NSCLC with a single-bone FDG lesion, lesion SUVmaxis useful for differential diagnosis. • CT features of the single-bone FDG lesions provide additional diagnostic value. • High NSCLC SUVmax, greater T stage, and FDG positive nodes also favor metastasis.

Entities:  

Keywords:  Bone metastasis; Fluorodeoxyglucose; Lung cancer; Positron-emission tomography

Mesh:

Substances:

Year:  2018        PMID: 30315418     DOI: 10.1007/s00330-018-5764-9

Source DB:  PubMed          Journal:  Eur Radiol        ISSN: 0938-7994            Impact factor:   5.315


  5 in total

1.  Clinical value of dual-phase F-18 sodium fluoride PET/CT for diagnosing bone metastasis in cancer patients with solitary bone lesion.

Authors:  Jeong Won Lee; Yong-Jin Park; Youn Soo Jeon; Ki Hong Kim; Jong Eun Lee; Sung Hoon Hong; Sang Mi Lee; Su Jin Jang
Journal:  Quant Imaging Med Surg       Date:  2020-11

2.  Efficacy Evaluation of Zoledronic Acid Combined with Chemotherapy in the Treatment of Lung Cancer Spinal Metastases on Computed Tomography Images on Intelligent Algorithms.

Authors:  Wei Cao; Peng Zhang; Nana Dong; Anwen Hu; Jiwen Xiao; Dexin Zou; Shulin Xiang; Yanxia Qi
Journal:  Comput Math Methods Med       Date:  2022-05-06       Impact factor: 2.809

3.  Predictive factors, preventive implications, and personalized surgical strategies for bone metastasis from lung cancer: population-based approach with a comprehensive cancer center-based study.

Authors:  Xianglin Hu; Wending Huang; Zhengwang Sun; Hui Ye; Kwong Man; Qifeng Wang; Yangbai Sun; Wangjun Yan
Journal:  EPMA J       Date:  2022-01-10       Impact factor: 6.543

4.  Clinical Value of Surveillance 18F-fluorodeoxyglucose PET/CT for Detecting Unsuspected Recurrence or Second Primary Cancer in Non-Small Cell Lung Cancer after Curative Therapy.

Authors:  Chae Hong Lim; Soo Bin Park; Hong Kwan Kim; Yong Soo Choi; Jhingook Kim; Yong Chan Ahn; Myung-Ju Ahn; Joon Young Choi
Journal:  Cancers (Basel)       Date:  2022-01-27       Impact factor: 6.639

5.  Development and validation of tumor-to-blood based nomograms for preoperative prediction of lymph node metastasis in lung cancer.

Authors:  Yili Fu; Xiaoying Xi; Yanhua Tang; Xin Li; Xin Ye; Bin Hu; Yi Liu
Journal:  Thorac Cancer       Date:  2021-06-24       Impact factor: 3.500

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.